drugset / Trial / NCT07339540
the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
NaSingle-groupOpen-labelTreatment
Summary
This study is designed as a single arm, open label, single center clinical trial to evaluate the safety, tolerability, efficacy, pharmacokinetic or pharmacodynamic characteristics of the investigational drug V001-BCMA in autoimmune disease.
Timeline
- Start
- 2025-11-04
- Primary completion
- 2028-10-30
- Completion
- 2028-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | V001-BCMA | Cell therapy | — | — |